Home/Pipeline/PNP/CD Synthetic Cell Combination

PNP/CD Synthetic Cell Combination

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Synlife

About Synlife

Synlife is an early-stage biotechnology company developing a novel therapeutic platform based on engineered Synthetic Cells. Its lead program, SOBER, targets the rapid removal of ethanol from the blood for alcohol poisoning, while a second program aims to locally activate chemotherapeutics within solid tumors. The company is privately held, pre-revenue, and backed by venture capital and government grants, positioning itself at the intersection of advanced drug delivery and synthetic biology.

View full company profile

Therapeutic Areas

Toxicology (Alcohol Poisoning)Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed